Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

CNE100000W45

Jointown Pharmaceutical stock research in summary

Jointown Pharmaceutical shares have a market-typical stock price level. They show above average growth, are safely financed and are good value. We recommend evaluating whether the future of the company Jointown Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.

Latest Obermatt Ranks


Value Rank	62
Growth Rank	83
Safety Rank	69
Combined Rank	89

Country	China
Industry	Health Care Distributors
Index	SSE Composite
Size class	XX-Large

January 8, 2021. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

Google: Jointown Pharmaceutical

News	Videos
Wikipedia about Jointown Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Jointown Pharmaceutical

RESEARCH HISTORY	2018	2019	2020	2021
VALUE
VALUE	74	73	62	62
GROWTH
GROWTH	46	61	83	83
SAFETY
SAFETY	62	59	69	69
COMBINED
COMBINED	69	83	89	89

Last update of Combined Rank: 8-Jan-2021. Financial reporting date used for calculating ranks: 30-Jun-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2018	2019	2020	2021
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	86	91	81	81
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	54	67	85	85
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	68	78	64	64
DIVIDEND YIELD
DIVIDEND YIELD	42	28	1	1
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	74	73	62	62

Last update of Value Rank: 8-Jan-2021. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2018	2019	2020	2021
REVENUE GROWTH
REVENUE GROWTH	42	70	72	72
PROFIT GROWTH
PROFIT GROWTH	80	56	72	72
STOCK RETURNS
STOCK RETURNS	26	40	82	82
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	46	61	83	83

Last update of Growth Rank: 30-Jun-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2018	2019	2020	2021
LEVERAGE
LEVERAGE	38	30	42	42
REFINANCING
REFINANCING	96	98	98	98
LIQUIDITY
LIQUIDITY	38	41	50	50
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	62	59	69	69

Last update of Safety Rank: 1-Jan-2021. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from January 8, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.